StockData
Xilio Therapeutics, Inc. logo

Xilio Therapeutics, Inc. (XLO) stock

XLONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3080% below fair value
$7.63+0.09 (+1.19%)

Close on Nov 18, 2026Market cap $44.12MP/E –Yield –

Xilio Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Xilio Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$31.37M. For fiscal 2025 it was -$41.98M. The highest annual figure on record is -$41.98M in fiscal 2025.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$41.98M–
FY2024Dec 31, 2024-$60.58M–
FY2023Dec 31, 2023-$79.13M–
FY2022Dec 31, 2022-$89.15M–
FY2021Dec 31, 2021-$75.04M–
FY2020Dec 31, 2020-$54.56M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$3.49M–
Q1 FY2026Mar 31, 2026-$14.11M–
Q4 FY2025Dec 31, 2025-$11.84M–
Q3 FY2025Sep 30, 2025-$1.93M–
Q2 FY2025Jun 30, 2025-$14.37M–
Q1 FY2025Mar 31, 2025-$13.85M–
Q4 FY2024Dec 31, 2024-$13.63M–
Q3 FY2024Sep 30, 2024-$14.76M–
Q2 FY2024Jun 30, 2024-$14.70M–
Q1 FY2024Mar 31, 2024-$17.49M–
Q4 FY2023Dec 31, 2023-$18.13M–
Q3 FY2023Sep 30, 2023-$17.36M–
Q2 FY2023Jun 30, 2023-$20.12M–
Q1 FY2023Mar 31, 2023-$23.53M–
Q4 FY2022Dec 31, 2022-$23.17M–
Q3 FY2022Sep 30, 2022-$20.21M–
Q2 FY2022Jun 30, 2022-$24.55M–
Q1 FY2022Mar 31, 2022-$21.22M–
Q4 FY2021Dec 31, 2021-$19.56M–
Q3 FY2021Sep 30, 2021-$15.96M–
Q2 FY2021Jun 30, 2021-$23.01M–
Q1 FY2021Mar 31, 2021-$16.52M–
Q4 FY2020Dec 31, 2020-$20.60M–
Q3 FY2020Sep 30, 2020-$14.62M–

More Xilio Therapeutics figures

See a number that looks wrong?